Let's take it into the lab.
We're seeking strategic partners, investors, and advisors to fund and execute experimental validation of a patent-pending Alzheimer's program.
Why partner now
A de-risked entry point into a $1T+ disease.
The hardest, most expensive part of early discovery is done. What remains is the experimental bridge — and that's where a partner's capital and capabilities compound.
- ✓Patent-pending, cross-validated asset.A novel ApoE4 corrector series with a filed provisional.
- ✓Clear, fundable next phase.Synthesis, binding confirmation, cell assays, ADME/PK.
- ✓A reusable platform.The engine extends to additional targets after Titan.
We are currently seeking
- ✓Wet-lab validation partnerSynthesis + SPR / ITC + a cell-based ApoE4 correction assay.
- ✓Strategic pharma / biotech partnerCNS / neurodegeneration or ApoE biology.
- ✓Bridge fundingExperimental validation and patent prosecution.
- ✓Scientific advisorsMedicinal chemistry, ApoE biology, translational AD.
Qualified partners can request the Titan data room — anonymized lead profiles, scoring workflow, ADMET summary, IP overview, and the proposed validation plan.
Start a conversation
Tell us a little about you. We typically respond within a few business days.
Message sent
Thank you — we've received your message and will respond within a few business days.
FAQ
Questions partners ask first.
No — and we say so plainly. All current results are computational predictions from physics-based and ML models. They establish a strong, de-risked starting point. Experimental confirmation (synthesis, binding, cell assays, ADME/PK) is exactly what the next, partner-funded phase delivers.
The lead series is novel composition of matter, protected by a filed provisional patent application. Methods are held as trade secrets and disclosed only under NDA.
We share results, reasoning, and validation openly. The architectures, design rules, scoring, and optimizer configuration that produce them are proprietary and available to qualified partners under NDA. The recipe is the company.
Yes. The engine is target-agnostic: any target with an experimentally observed binding site is a candidate. Titan (ApoE4) is the proof; additional programs follow as we're resourced.
A bridge to fund experimental validation and medicinal-chemistry optimization of the Titan series toward an IND-enabling candidate — plus the patent prosecution that protects it. Reach out and we'll walk you through the specifics.